{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T14:56:11Z","timestamp":1648911371078},"reference-count":13,"publisher":"Georg Thieme Verlag KG","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n          Masern-Mumps-R\u00f6teln- (MMR) und Varizellen-Impfung (VZV)\u2002Das 2020-Update der beruflichen MMR-Impfempfehlungen gilt in betroffenen Einrichtungen f\u00fcr alle Besch\u00e4ftigten und vereinfacht die Vorgaben: F\u00fcr die meisten Erwachsenen ab Jahrgang 1971 sind 2 dokumentierte Gaben notwendig. Das Masernschutzgesetz beinhaltet eine Impflicht f\u00fcr verschiedene Einrichtungen und Schulen.<\/jats:p><jats:p>\n          Pneumokokken-Impfung\u2002Aufgrund der Ver\u00e4nderung der zirkulierenden Serotypen seit Anwendung der Konjugatimpfstoffe bei Kindern empfiehlt die amerikanische ACIP diese nicht mehr f\u00fcr die Routine-Erwachsenenimpfung.<\/jats:p><jats:p>\n          Humane-Papillomaviren-Impfung (HPV)\u2002Beobachtungsstudien legen eine ausreichende Wirksamkeit von reduzierten Impfschemata mit 2 Dosen oder nur 1 Dosis nahe, Daten aus randomisierten Studien liegen aber noch nicht vor.<\/jats:p><jats:p>\n          Influenza-Impfung\u2002Eine Abschw\u00e4chung der Vakzineffektivit\u00e4t durch j\u00e4hrliche wiederholte saisonale Impfungen und auch im Verlauf einer Saison wird immer wieder festgestellt. Eine Ver\u00e4nderung der bestehenden Impfempfehlung ergibt sich daraus nicht.<\/jats:p><jats:p>\n          Ebola-Impfung\u2002Nach jahrelanger Entwicklung und Testung erfolgte die Zulassung der ersten Impfstoffe durch die EMA im November 2019 und Juli 2020.<\/jats:p><jats:p>\n          SARS-Coronavirus-2-Impfung (SARS-CoV-2)\u2002Aktuell werden mit massivem finanziellem Aufwand &gt;\u200a150 Vakzinkandidaten entwickelt, erste Phase-I\/II-Studien sind auch mit deutscher Beteiligung angelaufen. Damit k\u00f6nnte 2021 ein zugelassener Impfstoff zur Verf\u00fcgung stehen.<\/jats:p>","DOI":"10.1055\/a-0982-8894","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T22:40:46Z","timestamp":1602024046000},"page":"1464-1468","source":"Crossref","is-referenced-by-count":0,"title":["Neues zu Impfungen bei Erwachsenen"],"prefix":"10.1055","volume":"145","author":[{"given":"Ulrich","family":"Seybold","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, Sektion Klinische Infektiologie, Klinikum der Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"ref1","first-page":"313","article-title":"Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut \u2013 2019\/2020","volume":"34","author":"Robert-Koch-Institut","year":"2019","journal-title":"Epid Bull"},{"key":"ref2","first-page":"3","article-title":"Mitteilung der St\u00e4ndigen Impfkommission am Robert Koch-Institut: Empfehlung und wissenschaftliche Begr\u00fcndung f\u00fcr die Angleichung der beruflich indizierten Masern-Mumps-R\u00f6teln-(MMR-) und Varizellen-Impfung","volume":"2","author":"Robert-Koch-Institut","year":"2020","journal-title":"Epid\u00a0Bull"},{"key":"ref3","first-page":"148","article-title":"Gesetz f\u00fcr den Schutz vor Masern und zur St\u00e4rkung der Impfpr\u00e4vention (Masernschutzgesetz)","volume":"6","author":"Der Deutsche Bundestag","year":"2020","journal-title":"Bundesgesetzblatt"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged \u2265 65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"A Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e1918571","DOI":"10.1001\/jamanetworkopen.2019.18571","article-title":"Prevalence of Human Papillomavirus Infection by Number of Vaccine Doses Among US Women","volume":"2","author":"K Sonawane","year":"2019","journal-title":"JAMA Netw Open"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.vaccine.2019.12.017","article-title":"Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials","volume":"38","author":"H S Whitworth","year":"2020","journal-title":"Vaccine"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/infdis\/jiz555","article-title":"Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses","volume":"221","author":"L E Markowitz","year":"2020","journal-title":"J Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz434","article-title":"Repeated Seasonal Influenza Vaccination-How Much is Too Much of a Good Thing?","author":"H D Stacey","year":"2019","journal-title":"J Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12916-018-1239-8","article-title":"The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis","volume":"17","author":"L C Ramsay","year":"2019","journal-title":"BMC Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/cid\/ciz452","article-title":"Waning of influenza vaccine protection: Exploring the trade-offs of changes in vaccination timing among older adults","volume":"70","author":"J M Ferdinands","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz433","article-title":"Evidence that blunted CD4 T cells responses underlie deficient protective antibody responses to influenza vaccines in repeatedly vaccinated human subjects","author":"K A Richards","year":"2019","journal-title":"J Infect Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.7326\/M19-0735","article-title":"Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults: A Randomized Clinical Trial","volume":"172","author":"O Pleguezuelos","year":"2020","journal-title":"Ann Intern Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1473-3099(20)30248-6","article-title":"Safety and immunogenicity of a\u00a0modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial","volume":"20","author":"T Koch","year":"2020","journal-title":"Lancet Infect Dis"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-0982-8894.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T22:41:09Z","timestamp":1602024069000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-0982-8894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":13,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2020,10,6]]},"published-print":{"date-parts":[[2020,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-0982-8894","relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}